Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): A pilot study in human gliomas

Clinical Cancer Research

Volumn 5, Issue 5, 1999, Pages 1025-1033

  Merlo, Adrian ^a,b   Hausmann, Oliver ^b   Wasner, Morten ^b   Steiner, Philipp ^b   Otte, Andreas ^b   Jermann, Eduard ^b   Freitag, Peter ^b   Reubi, Jean Claude ^c   Müller Brand, Jan ^b   Gratzl, Otmar ^b   Mäcke, Helmut R ^b  

^a Neurologische Universitatsklinik Basel   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CHELATING AGENT; OCTREOTIDE[1 DEXTRO PHENYLALANINE 3 TYROSINE]; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG BINDING; DRUG DISTRIBUTION; DRUG TARGETING; DRUG UPTAKE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INTRATUMORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ADULT; ASTROCYTOMA; BINDING, COMPETITIVE; BRAIN EDEMA; BRAIN NEOPLASMS; DIFFUSION; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OCTREOTIDE; OLIGODENDROGLIOMA; PILOT PROJECTS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RECEPTORS, SOMATOSTATIN; STEREOTAXIC TECHNIQUES; TISSUE DISTRIBUTION; YTTERBIUM;

EID: 0032900726     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Black, P. M. Brain Tumors. N. Engl. J. Med., 324: 1555-1564, 1991.
2. Berger, M. S., Leibel, S. A., Briner, J. A., Finlay, J. L., and Levin, V. A. Primary central nervous system tumors of the supratentorial compartment. In: Levin V. A. (ed.), Cancer in the Nervous System, pp. 57-126, New York: Churchill Livingstone, 1995.
3. Shaw, E. G., Scheithauer, B. W., and O'Fallon, J. R. Management of supratentorial low-grade gliomas. Semin. Radiat. Oncol., 1: 23-31, 1991.
4. Shaw, E. G., Scheithauer, B. W., O'Fallon, J. R., Tazelaar, H. D., and Dudley, H. D. Oligodendrogliomas: The Mayo Clinic experience. J. Neurosurg., 76: 428-434, 1992.
5. Walker, M. D., Green, S. B., Byar, D. P., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., Owens, G., Ransohoff, J., Robertson, J. T., Shapiro, W. R., Smith, K. R., Wilson, C. B., and Strike, T. A. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med., 303: 1323-1329, 1980.
6. Garfield, J., Dayan, A. D., and Weller, R. O. Postoperative intracavitary chemotherapy of malignant supratentorial astrocytomas using BCNU. Clin. Oncol., 1: 213-222, 1975.
7. Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, M., Vick, N. A., Black, K., Sisti, M., Brem, S., and Mohr, G. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet, 345: 1008-1012, 1995.
8. 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res., 55: 5952s-5956s, 1995.
9. Papanastassiou, V., Pizer, B. L., Coakham, H. B., Bullimore, J., Zananiri, T., and Kemshead, J. T. Treatment of recurrent and cystic malignant glioma by a single intracavitary injection of I-131 monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Br. J. Cancer, 67: 144-151, 1993.
10. Laske, D. W., Youle, R. J., and Oldfield, E. H. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat. Med., 3: 1362-1368, 1997.
11. Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. L., DeVroom, H. L., Otto, E., Long, Z., Chiang, Y., McGarrity, G. J., Muul, L. M., Katz, D., Blaese, R. M., and Oldfield, E. H. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med., 3: 1354-1361, 1997.
12. Otte, A., Mueller-Brand, J., Dellas, S., Nitzsche, E. U., Herrmann, R., and Maecke, H. R. Yttrium-90-labelled somatostatin analogue for cancer treatment. Lancet, 351: 417-418, 1998.
13. Reubi, J. C., Horisberger, U., Lang, W., Koper, J. W., Braakman, R., and Lamberts, S. W. J. Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation dependent relationship in glial tumors. Am. J. Pathol, 134: 337-344, 1989.
14. 3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur. J. Nucl. Med., 24: 368-371, 1997.
15. Otte, A., Jermann, E., Béhé, M., Götze, M., Bucher, H. C., Roser, H. W., Heppeler, A., Müller-Brand, J., and Mäcke, H. R. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur. J. Nucl. Med., 24: 792-795, 1997.
16. Ruser, G., Ritter, W., and Maecke, H. R. Synthesis and evaluation of two new bifunctional carboxymethylated tetraazamacrocyclic chelating agents for protein labeling with indium-111. Bioconj. Chem., 1: 345-349, 1990.
17. 111In-labelled SCN-BZ-DTPA-BC-2 MAB following locoregional injection into glioblastomas. Int. J. Cancer, 71: 810-816, 1997.
18. Reubi, J. C., Probst, A., Cortès, R., and Palacios, J. M. Distinct topographical localisation of two somatostatin receptor subpopulations in the human cortex. Brain Res., 406: 391-396, 1987.
19. MIRD Pamphlet, No. 11. New York: Society of Nuclear Medicine, 1985.
20. Loevinger, R., and Berman, M. A schema for absorbed dose calculation for biologically distributed radionuclides. MIRD Pamphlet No. I. J. Nucl. Med., 9 (Suppl. 1): 7-14, 1968.
21. Kleihues, P., Burger, P. C., and Scheithauer, B. W. Histological typing of tumours of the Central Nervous System. WHO International Histological Classification of Tumours. Berlin: Springer, 1993.
22. Zalutsky, M. R., Moseley, R. P., Benjamin, J. C., Colapinto, E. V., Fuller, G. N., Coakham, H. P., and Bigner, D. D. Monoclonal antibody and F(ab′)2 fragment delivery to turner in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res., 50: 4105-4110, 1990.
23. Fisher, J. B., Bauman, G. S., Leighton, C. E., Stitt, L., Cairncross, J. G., and Macdonald, D. R. Low-grade glioma in children: tumor volume response to radiation. J. Neurosurg., 88: 969-974, 1998.
24. Goldsmith, B. J., Wara, W. M., and Wilson, C. B. Postoperative irradiation for subtotally resected meningiomas. J. Neurosurg., 80: 195-201, 1994.
25. Krenning, E. P., Kwekkeboom, D. J., Pauwels, S., Kvols, L. K., and Reubi, J. C. Somatostatin receptor scintigraphy. In: L. M. Freeman (ed.), Nuclear Medicine Annual 1995, pp. 1-48. New York: Raven Press Ltd., 1995.
26. Haldemann, A. R., Rösler, H., Barth, A., Waser, B., Geiger, L., Godoy, N., Markwalder, R. V., Seiler, R. W., Sulzer, M., and Reubi, J. C. Somatostatin receptor scintigraphy in patients with CNS tumors: the role of blood brain barrier permeability. J. Nucl. Med., 36: 403-410, 1995.
27. Jain, R. K. Physiological resistance to the treatment of solid tumors. In: B. A. Teicher (ed.), Drug Resistance in Oncology, pp. 87-105. New York: Marcel Dekker, Inc., 1993.
28. Bakay, L. The extracellular space in brain tumors. I. Morphological considerations. Brain, 93: 693-698, 1970.
29. Sampson, J. H., Cokgor, I., Akabani, G., Friedman, A., Coleman, E., Friedman, H., McLendon, R., Zhou, X., Bigner, S., Pegram. C., Wikstrand, C., Vick, N., Paleologos, N., Zalutsky, M., and Bigner, D. Radiolabeled anti-tenascin monoclonal antibody in recurrent malignant brain tumors. Proc. Am. Assoc. Cancer Res., 39: 324-325, 1998.